Floatz Rating
B62/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07218692CT.gov RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | — | Not Yet Recruiting | — | — | — |
NCT06661720CT.gov Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | — | Recruiting | — | — | — |
NCT06053658CT.gov Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT04987203CT.gov Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | — | Completed | — | — | — |
NCT03136627CT.gov Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | — | Completed | — | — | — |
NCT02627963CT.gov A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) | — | Completed | — | — | — |
NCT01834183CT.gov Tivozanib + Gemcitabine in Metastatic RCC | — | Withdrawn | — | — | — |
NCT01769885CT.gov Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer | — | Withdrawn | — | — | — |
NCT01673386CT.gov A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC | — | Terminated | — | — | — |
NCT01297244CT.gov A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma | — | Completed | — | — | — |
Show 4 more trialsShow fewer
NCT01076010CT.gov An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). | — | Completed | — | — | — |
NCT01030783CT.gov A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma | — | Completed | — | — | — |
NCT00563147CT.gov A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma | — | Completed | — | — | — |
NCT00502307CT.gov A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tivozanib (this asset) | City of Hope Medical Center | P3 | B · 62 |
| Sorafenib | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P4 | BBB |
| Pazopanib | Imbioray (Hangzhou) Biomedicine Co., Ltd. | P4 | BBB |
| Belzutifan | Vall d'Hebron Institute of Oncology | P3 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Interferon-Alfa-2A | Central European Society for Anticancer Drug Research | P3 | BB |
| Everolimus | Merck Sharp & Dohme LLC | P4 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P4 | BB |
+42 more in the Renal Cell Carcinoma cohort
Other indications for Tivozanib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P2 | B · 58 |
| Nonpapillary Renal Cell Carcinoma | — | P3 | B · 57 |
| Renal Pelvis Carcinoma | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tivozanib in Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tivozanib-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →